5 Key Takeaways

• 1

  Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center received a 3-year SU2C grant to improve gastroesophageal cancer care.

• 2

  Approximately 70% of gastroesophageal cancer patients do not respond to standard treatments, highlighting the need for novel therapies.

• 3

  Research indicates chromosomal instability in gastroesophageal cancer leads to immune evasion and poorer treatment outcomes.

• 4

  The grant will fund investigations into immune evasion mechanisms using whole-genome sequencing of tumors.

• 5

  A new clinical trial will evaluate treatment strategies targeting HER2-negative and HER2-positive gastroesophageal cancer patients.